Business as usual in Amsterdam
The tremendous success of last year’s BIO Europe Spring in Barcelona was hard to beat. But the follow-up this year in Amsterdam organised by EBD Group together with Health Holland crystallised as a worthy successor.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2128 entries already.
Entries by Thomas Gabrielczyk
MYR Pharma completes chronic hepatitis delta POC trial
German MYR Pharma has completed a proof of concept Phase IIb trial with its first-in-class hepatitis D entry inhibitor Myrcludex B, which is developed under the European Medicines Agency’s PRIME scheme.
Sanofi’s alirocumab improves cardiovascular event rate over statins
Alirocumab, Sanofi’ s/Regeneron’s PCSK9 inhibitor, in combination with statins has met the endpoint of reducing the number of major adverse cardiovascular events (MACE) over statin monotherapy in 18,924 high-risk patients.
Medimmune finds target against systemic sclerosis
Researchers at Medimmune, AstraZeneca’s biologics arm, have identified a mechanism that drives the autoimmune disease systemic sclerosis.
Bioprocessing challenges in the focus
About 300 bioeconomy experts from science and business came together in Strasbourg for the first edition of BIOKET to discuss up-scaling challenges, new processing technologies as well as the potential of synthetic biology and digitalization.
Learning to listen to your gut
The adage you are what you eat’ is more than folk wisdom. Evidence that the food you ingest has a major impact on your health grows by the day. It’s now clear the bacteria that colonise the skin and gut from birth on are key sensors for environmental triggers in chronic diseases of civilisation. Ever since research showed that restoring microbiome balance cures 90% of all Clostridium difficile infections, food manufacturers, pharma companies and independent teams have been tracking it in other indications – including multiple sclerosis.
Sanofi to outsource antiinfectives R&D to Evotec
Evotec and Sanofi want to create an Evotec-led infectious disease open innovation R&D platform at Sanofi’s antiinfectives hub in Lyon. Talks are expected to close in H1/2018 with an option agreement.
Experts forecast the industry’s biggest developments at Pharmapack Europe
Personalised medicines, intelligent packaging and FDA deadlines seen as major trends for pharma packaging in 2018.
Heidelberg Pharma inks US$334m R&D contract with Magenta Therapeutics
Under an exclusive licence option agreement, Heidelberg Pharma will develop ATACs (alpha-amanitin antibody conjugates) for Magenta Therapeutics Inc. across several targeted conditioning programmes for bone marrow transplants.
Investors keen to put money into AMR SMEs
Investments into new drugs to tackle antimicrobial resistance (AMR) are set to boost the participation of SMEs. At the 11th Berlin Conference on Life Sciences, two new financing initiatives, which focus on innovations developed by SMEs, were presented to 200+ AMR stakeholders.